Research Letters: What do clinicians think about psychedelic-assisted therapy? An Australian perspective

Australian Institute of Health and Welfare (2022) Health workforce, Australian Government. Available at: www.aihw.gov.au/reports/workforce/health-workforce (accessed 5 December 2023).

Australian Institute of Health and Welfare (2024) Ecstasy in the NDSHS, Australian Government. Canberra, ACT, Australia: Australian Institute of Health and Welfare.

Barnett BS Beaussant Y King F , et al. (2022) Psychedelic knowledge and opinions in psychiatrists at two professional conferences: An exploratory survey. Journal of Psychoactive Drugs 54: 269–277.

Barnett BS Siu WO Pope HG (2018) A survey of American psychiatrists’ attitudes toward classic hallucinogens. The Journal of Nervous and Mental Disease 206: 476–480.

Benjamini Y Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B 57: 289–300.

Berger JJ Fitzgerald PB (2023) The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists. Australasian Psychiatry 31: 190–194.

Bouso JC DosSantos RG Alcázar-Córcoles MÁ , et al. (2018) Serotonergic psychedelics and personality: A systematic review of contemporary research. Neuroscience & Biobehavioral Reviews 87: 118–132.

Cavanna F Pallavicini C Milano V , et al. (2021) Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. Journal of Psychedelic Studies 5: 83–93.

Davis AK Agin-Liebes G España M , et al. (2022) Attitudes and beliefs about the therapeutic use of psychedelic drugs among psychologists in the United States. Journal of Psychoactive Drugs 54: 309–318.

MacLean KA Johnson MW Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 25: 1453–1461.

Page LA Rehman A Syed H , et al. (2021) The readiness of psychiatrists to implement psychedelic-assisted psychotherapy. Frontiers in Psychiatry 12: 743599.

Skinner N McEntee A Roche A (2020) Australia’s Alcohol and Other Drug Workforce: National Survey Results 2019-2020. Adelaide, South Australia: National Centre for Education and Training on Addiction (NCETA), Flinders University. Available at: https://nceta.flinders.edu.au/application/files/1216/0748/4166/NCETA-NAODWS-19-20-Draft14.pdf (accessed 23 April 2024).

Solmi M Chen C Daure C , et al. (2022) A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology 64: 44–60.

Therapeutic Goods Administration (2023) Prescribe MDMA or psilocybin (psychiatrists). Available at: www.tga.gov.au/products/unapproved-therapeutic-goods/mdma-and-psilocybin-hub/prescribe-mdma-or-psilocybin-psychiatrists (accessed 28 November 2023).

Wright DJ Colagiuri B Glozier N (2022) Evaluating the attitudes of mental health professionals towards trials of MDMA: A randomised vignette trial. BMJ Open 12: e060360.